Asanuma Masato, Miyazaki Ikuko
Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikatacho, Okayama 700-8558, Japan.
Curr Pharm Des. 2008;14(14):1428-34. doi: 10.2174/138161208784480153.
A number of experimental studies using parkinsonian models have revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) have neuroprotective properties against dopaminergic neurotoxicity not only by their cyclooxygenase-inhibiting effect but also by other specific properties or some unknown pharmacological effects. This article reviews heterogeneous pharmacological properties of NSAIDs including inhibitory effect against nitric oxide synthesis, agonistic action for peroxisome proliferator-activated receptor gamma, or possible suppressive effects against dopamine quinone generation, and also reviews their neuroprotective effects in the experimental parkinsonian models and pathogenesis of Parkinson's disease. Several epidemiological studies recently clarified that the use of nonaspirin NSAIDs but not aspirin was associated with a lower prevalence of Parkinson's disease, in contrast with neuroprotective effects of aspirin in the experimental studies. It also discusses the discrepancy between results in the experimental parkinsonian models and epidemiological data in prevalence of Parkinson's disease on the effects of NSAIDs.
一些使用帕金森病模型的实验研究表明，非甾体抗炎药（NSAIDs）不仅通过其环氧化酶抑制作用，还通过其他特定特性或一些未知的药理作用，对多巴胺能神经毒性具有神经保护特性。本文综述了NSAIDs的多种药理特性，包括对一氧化氮合成的抑制作用、对过氧化物酶体增殖物激活受体γ的激动作用，或对多巴胺醌生成的可能抑制作用，还综述了它们在实验性帕金森病模型中的神经保护作用以及帕金森病的发病机制。最近的几项流行病学研究表明，与阿司匹林在实验研究中的神经保护作用相反，使用非阿司匹林类NSAIDs而非阿司匹林与帕金森病的较低患病率相关。本文还讨论了实验性帕金森病模型的结果与NSAIDs对帕金森病患病率影响的流行病学数据之间的差异。
